SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rose-Ped A,Bellm LA,Epstein JB,Trotti A,Gwede C,Fuchs HJ. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs. 2002; 25: 461467.
  • 2
    Talmi YP. Quality of life issues in cancer of the oral cavity. J Laryngol Otol. 2002; 116: 785790.
  • 3
    Vissink A,Jansma J,Spijkervet FK,Burlage FR,Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003; 14: 199212.
  • 4
    Epstein JB,Emerton S,Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck. 1999; 21: 111.
  • 5
    Trotti A,Bellm LA,Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66: 253262.
  • 6
    Rubenstein EB,Peterson DE,Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100( 9 suppl): 20262046.
  • 7
    Pico JL,Avila-Garavito A,Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998; 3: 446451.
  • 8
    Mabro M,Faivre S,Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Safety. 1999; 21: 367387.
  • 9
    Airoldi M,Cortesina G,Giordano C, et al. Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004; 130: 161166.
  • 10
    Vokes EE,Kies MS,Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000; 18: 16521661.
  • 11
    Bernier J,Domenge C,Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 19451952.
  • 12
    Cooper JS,Pajak TF,Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 19371944.
  • 13
    Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000; 47: 112.
  • 14
    Vissink A,Burlage FR,Spijkervet FK,Jansma J,Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003; 14: 213225.
  • 15
    Spielberger R,Stiff P,Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351: 25902598.
  • 16
    Epstein JB,Robertson M,Emerton S,Phillips N,Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001; 23: 389398.
  • 17
    Duncan GG,Epstein JB,Tu D, et al. Quality of life, mucositis and xerostomia from radiotherapy for head and neck cancers. A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005; 27: 421428.
  • 18
    Rogers SN,Gwanne S,Lowe D,Humphris G,Yueh B,Weymuller EAJr. The addition of mood and anxiety domains to the University of Washington Quality of Life Scale. Head Neck. 2002; 24: 521529.
  • 19
    Weymuller EA,Yueh B,Deleyiannis FW,Kuntz AL,Alsarraf R,Coltrera MD. Quality of life in patients with head and neck cancer: lessons learned from 549 prospectively evaluated patients. Arch Otolaryngol Head Neck Surg. 2000; 126: 329336.
  • 20
    Weymuller EAJr,Alsarraf R,Yueh B,Deleyiannis FW,Coltrera MD. Analysis of the performance characteristics of the University of Washington Quality of Life instrument and its modification (UW-QOL-R). Arch Otolaryngol Head Neck Surg. 2001; 127: 489493.
  • 21
    Bjordal K,Kaasa S,Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994; 28: 847856.
  • 22
    Bjordal K,Ahlner-Elmqvist M,Tollesson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients.EORTC Quality of Life Study Group. Acta Oncol. 1994; 33: 879885.
  • 23
    Bjordal K,Hammerlid E,Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999; 17: 10081019.
  • 24
    Stiff P,Erder H,Bensinger W, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). J Bone Marrow Transplantation. 2006; 37: 393401.
  • 25
    Aaronson NK. Methodological issues in assessing quality of life of cancer patients. Cancer. 1991; 67( 3 Suppl): 844850.
  • 26
    List MA,D'Antonio LL,Cella DF, et al. The Performance Status Scale for head and neck cancer patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer. 1996; 77: 22942301.
  • 27
    Cella D,Paul D,Yount S,Winn R,Chang CH,Banik D,Weeks J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest. 2003; 21: 526535.
  • 28
    Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT Scales). Evanston, Ill: Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University; 1997.
  • 29
    Fleiss JL. The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons, Inc.; 1986.
  • 30
    Cella D,Eton DT,Lai J-S,Peterman AH,Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002; 24: 547561.
  • 31
    Hays RD,Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics. 2000; 18: 419423.
  • 32
    Small EJ,Meyer M,Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000; 18: 14401450.
  • 33
    Stiff P,Emmanouilides C,Bensinger W, et al. Palifermin (Kepivance™) reduces patient reported mouth and throat soreness and improves patient functioning in the hematopoietic stem cell transplantation setting: phase 3 trial results. J Clin Oncol. 2006: 24: 51865193.
  • 34
    Cella D,Pulliam J,Fuchs H, et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer. 2003; 98: 406412.
  • 35
    Loprinzi CL. The Epstein/Schubert article reviewed. Oncology. 2003; 17: 17671779; discussion, 1779–1782, 1791–1792.
  • 36
    Meropol NJ,Somer RA,Guytheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003; 21: 14521458.